These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6346614)

  • 21. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.
    Storb R; Deeg HJ; Whitehead J; Appelbaum F; Beatty P; Bensinger W; Buckner CD; Clift R; Doney K; Farewell V
    N Engl J Med; 1986 Mar; 314(12):729-35. PubMed ID: 3513012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. rhGM-CSF after allogeneic bone marrow transplantation from unrelated donors: a pilot study of cyclosporine and prednisone as graft-versus-host disease prophylaxis.
    Nemunaitis J; Anasetti C; Bianco JA; Hasen J; Singer JW
    Leuk Lymphoma; 1993 Jun; 10(3):177-81. PubMed ID: 8220115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of serum cyclosporine concentration with renal dysfunction in marrow transplant recipients.
    Kennedy MS; Yee GC; Mcguire TR; Leonard TM; Crowley JJ; Deeg HJ
    Transplantation; 1985 Sep; 40(3):249-53. PubMed ID: 3898489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine.
    Kennedy MS; Deeg HJ; Storb R; Doney K; Sullivan KM; Witherspoon RP; Appelbaum FR; Stewart P; Sanders J; Buckner CD
    Am J Med; 1985 Jun; 78(6 Pt 1):978-83. PubMed ID: 3893112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclosporine and methylprednisolone for prophylaxis of acute graft-versus-host disease.
    Shepherd JD; Shore TB; Reece DE; Barnett MJ; Klingemann HG; Buskard NA; Phillips GL
    Bone Marrow Transplant; 1988 Nov; 3(6):553-8. PubMed ID: 3063323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose cyclosporine and corticosteroids for prophylaxis of acute and chronic graft-versus-host disease.
    Schwinghammer TL; Bloom EJ; Rosenfeld CS; Wilson JW; Przepiorka D; Shadduck RK
    Bone Marrow Transplant; 1995 Jul; 16(1):147-54. PubMed ID: 7581115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease.
    Yau JC; LeMaistre CF; Zagars GK; Williams LA; Meneghetti CM; Luke DR; Dunphy FR; Spinolo JA; Jagannath S; Spitzer G
    Bone Marrow Transplant; 1990 Apr; 5(4):269-72. PubMed ID: 2337738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-cell frequency analysis does not predict the incidence of graft-versus-host disease in HLA-matched sibling bone marrow transplantation.
    Wang XN; Taylor PR; Skinner R; Jackson GH; Proctor SJ; Hedley D; Dickinson AM
    Transplantation; 2000 Aug; 70(3):488-93. PubMed ID: 10949192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation.
    Wingard JR; Nash RA; Przepiorka D; Klein JL; Weisdorf DJ; Fay JW; Zhu J; Maher RM; Fitzsimmons WE; Ratanatharathorn V
    Biol Blood Marrow Transplant; 1998; 4(3):157-63. PubMed ID: 9923414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation.
    Ogawa H; Soma T; Hosen N; Tatekawa T; Tsuboi A; Oji Y; Tamaki H; Kawakami M; Ikegame K; Murakami M; Fujioka T; Kim EH; Oka Y; Sugiyama H
    Transplantation; 2002 Jul; 74(2):236-43. PubMed ID: 12151737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.
    Ostronoff F; Ostronoff M; Souto-Maior AP; Domingues M; Sucupira A; Manso DA; de Lima AK; Monteiro PG; Florêncio R; Calixto R
    Clin Transplant; 2009; 23(1):33-8. PubMed ID: 18727660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of cyclosporine-induced syngeneic graft-versus-host disease in bone marrow transplantation by UV-B irradiated bone marrow cells.
    Ohajekwe OA; James T; Hardy MA; Oluwole SF
    Bone Marrow Transplant; 1995 Apr; 15(4):627-32. PubMed ID: 7655391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
    Mengarelli A; Iori AP; Romano A; Cerretti R; Cerilli L; De Propris MS; Fenu S; Moleti ML; De Felice L; Girelli G; Arcese W
    Haematologica; 2003 Mar; 88(3):315-23. PubMed ID: 12651271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease.
    Sullivan KM; Witherspoon RP; Storb R; Deeg HJ; Dahlberg S; Sanders JE; Appelbaum FR; Doney KC; Weiden P; Anasetti C
    Blood; 1988 Aug; 72(2):555-61. PubMed ID: 3042042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
    Koga Y; Nagatoshi Y; Kawano Y; Okamura J
    Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.
    Chao NJ; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM
    N Engl J Med; 1993 Oct; 329(17):1225-30. PubMed ID: 8413388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
    Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S
    Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The correlation of cyclosporine serum and whole blood concentrations with toxicity and efficacy after human marrow transplantation.
    Britton K; Atkinson K; Downs K; Biggs J
    Transplant Proc; 1985 Apr; 17(2):1667-70. PubMed ID: 3885501
    [No Abstract]   [Full Text] [Related]  

  • 40. Cyclosporine administration practices on bone marrow transplant units: a national survey.
    Caudell KA; Adams J
    Oncol Nurs Forum; 1990; 17(4):563-8. PubMed ID: 2119035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.